<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02337335</url>
  </required_header>
  <id_info>
    <org_study_id>NCSRR01</org_study_id>
    <nct_id>NCT02337335</nct_id>
  </id_info>
  <brief_title>Assesment of a Predictive Model Dosage of EPO in Hemodialysis Patients</brief_title>
  <official_title>Assesment of a Predictive Model Dosage of EPO in Hemodialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NephroCare Spain</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Francesc Moreso</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>NephroCare Spain</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assesment of a predictive model of anemia management: Dosage of erythropoietin (EPO) and Iron&#xD;
      adminsitration in hemodialysis patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anemia in patients on hemodialysis (HD ) is common and although usually responds well to&#xD;
      treatment with Erythropoiesis Stimulating Agents (ESAs ) , this dosage , based on different&#xD;
      clinical protocols , often ignores the high variability inter- and intra -individual in&#xD;
      patient response . The result leads to swings in the objective by different dosage range that&#xD;
      is associated with multiple risks and side effects. There are artificial intelligence-based&#xD;
      optimization methods that predict treatment with ESAs in maintaining patient hemoglobin&#xD;
      target range . So far the model has been validated for the long half-life of EPO (&#xD;
      darbepoetin ) with promising results.&#xD;
&#xD;
      HYPOTHESIS: Maintaining patients in Hb levels ESAs range using short half-life , avoid the&#xD;
      one hand , the need for transfusions and, secondly , the levels exceeding the upper range (&#xD;
      overshooting ), preventing the onset of a increased cardiovascular risk events.&#xD;
&#xD;
      RELEVANCE:The results allow us to validate the model with short half-life ESAs optimizing the&#xD;
      management of anemia and improving comorbidity associated with overdosage.&#xD;
&#xD;
      SUMMARY:&#xD;
&#xD;
      Prospective observational study of paired data. Data obtained from the data base Euclid .&#xD;
      Data will be collected by clinical teams according to standard clinical practice. Informed at&#xD;
      the time of admission to the clinic consent will be obtained . All patient data including to&#xD;
      november 15th 2014 and who have completed the study period to 30 april 2015. The results will&#xD;
      be compared with those prior to the patient's inclusion in the study were processed.&#xD;
&#xD;
      To detect a difference of 10% in the percentage of patients in the hemoglobin target range&#xD;
      after intervention (from 70% to 80%) we will need a minimum sample size of 268 patients&#xD;
      assuming an alpha error of 0.05, a beta error of 0.2 and a correlation between both&#xD;
      observations of 0.1.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Crossover</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Erythropoietin stimulating agents dosage</measure>
    <time_frame>at six months</time_frame>
    <description>u/kg/week</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intravenous Iron dosage</measure>
    <time_frame>at six months</time_frame>
    <description>mg/mont</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>anemia parameters</measure>
    <time_frame>at six months</time_frame>
    <description>ferritin (Âµg/l), ESA resistance index, transferrin index (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular events</measure>
    <time_frame>at six months</time_frame>
    <description>hospitalisation (days of hospitalisation), death and death cause,</description>
  </secondary_outcome>
  <enrollment type="Anticipated">268</enrollment>
  <condition>Anemia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients on hemodialysis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  &gt; 18 Years&#xD;
&#xD;
          -  &gt; 3 Months on HD / OLHDF&#xD;
&#xD;
          -  Treated with ESAs( epoBeta ) from&gt; 3 Months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chronic inflammatory diseases&#xD;
&#xD;
          -  Liver Cirrhosis&#xD;
&#xD;
          -  Active Neoplasms&#xD;
&#xD;
          -  Immunosuppression or other antiinflammatory medication&#xD;
&#xD;
          -  Patients who do not require treatment with ESAs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rosa Ramos, MD, Ph D</last_name>
    <phone>+34 630909907</phone>
    <email>rosa.ramos@fmc-ag.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>NephroCare Spain</name>
      <address>
        <city>Tres Cantos</city>
        <state>Madrid</state>
        <zip>28760</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosa Ramos, MD, Ph</last_name>
      <phone>913276650</phone>
      <phone_ext>134</phone_ext>
      <email>rosa.ramos@fmc-ag.com</email>
    </contact>
    <contact_backup>
      <last_name>Javier Varas</last_name>
      <phone>913276650</phone>
      <phone_ext>233</phone_ext>
      <email>javier.varas@fmc-ag.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <study_first_submitted>November 3, 2014</study_first_submitted>
  <study_first_submitted_qc>January 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2015</study_first_posted>
  <last_update_submitted>January 8, 2015</last_update_submitted>
  <last_update_submitted_qc>January 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>NephroCare Spain</investigator_affiliation>
    <investigator_full_name>Rosa Ramos</investigator_full_name>
    <investigator_title>Medical Department Management</investigator_title>
  </responsible_party>
  <keyword>Hemodialyisis</keyword>
  <keyword>Predictive Model</keyword>
  <keyword>ESAs</keyword>
  <keyword>patients</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

